Where Vir Biotechnology Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have given Vir Biotechnology (NASDAQ:VIR) mostly bullish ratings in the last quarter, with 4 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $44.6, representing a 26.28% decrease from the previous average price target of $60.50.
July 21, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have given Vir Biotechnology mostly bullish ratings, but the average 12-month price target has decreased by 26.28%.
While the majority of analysts are bullish on Vir Biotechnology, the significant decrease in the average 12-month price target could indicate a potential decrease in the stock's value in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100